Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Nyxoah ( (NYXH) ).
Nyxoah SA has announced a transparency notification regarding a passive threshold crossing by Cochlear Investments Pty Ltd, which now holds 14.999% of Nyxoah’s voting rights. This change reflects a slight decrease from a previous 15.04% stake, indicating a minor shift in shareholder structure, which may influence future company decisions and stakeholder interests.
The most recent analyst rating on (NYXH) stock is a Buy with a EUR12.00 price target. To see the full list of analyst forecasts on Nyxoah stock, see the NYXH Stock Forecast page.
More about Nyxoah
Nyxoah operates in the medical technology industry, focusing on the development and commercialization of innovative solutions for sleep apnea treatment. The company is known for its minimally invasive neurostimulation therapy aimed at addressing obstructive sleep apnea, a prevalent condition affecting millions globally.
Average Trading Volume: 58,712
Current Market Cap: €185.6M
For an in-depth examination of NYXH stock, go to TipRanks’ Overview page.